The financial information of AbbVie Inc. and its subsidiaries details revenues, expenses, earnings per share, assets, liabilities, equity, and cash flows for the company during specified time frames. It sheds light on key financial metrics such as net earnings, operating expenses, interest expenses, comprehensive income, and more, including changes in stocks, investments, liabilities, and equity. Additionally, AbbVie shares profits and losses with Genentech from the development and commercialization of Venclexta. The text outlines the financial relationship, cost-sharing details, goodwill, and intangible assets of AbbVie, including amortization expenses and impairment charges related to products like Vuity. AbbVie's integration and restructuring plans, financial instruments, risk management policies, and use of derivative instruments like swaps, hedges, and foreign exchange contracts are discussed, including gains and losses from derivative instruments and fair value measures.
The text discusses AbbVie Inc.'s financial condition and results of operations for the three and nine months ended September 30, 2022, along with strategic objectives, recent global events impact, and research and development developments. The company reported a 4% growth in worldwide net revenues, driven by its immunology, neuroscience, and aesthetics portfolios. Key products like Skyrizi and Rinvoq showed substantial revenue growth. The text also covers aspects like gross margin, expenses, income tax, financial position, liquidity, and credit risk. AbbVie's critical accounting policies and forward-looking statements are also highlighted, cautioning about risks and uncertainties that could impact the company's performance.
Please refer to Item 7A in AbbVie's Annual Report for a detailed discussion on the company's market risk, including quantitative and qualitative disclosures.
The text discusses the evaluation of disclosure controls and procedures by AbbVie's CEO and CFO, confirming the effectiveness of these controls to ensure accurate and timely disclosure of information to the SEC. It also mentions there were no significant changes in AbbVie's internal control over financial reporting during the quarter ended September 30, 2022. The text highlights the inherent limitations of controls in preventing all errors and fraud, emphasizing that they offer reasonable but not absolute assurance. The design of control systems considers resource constraints and the potential for errors, fraud, or circumvention by individuals, collusion, or management override. Overall, controls are subject to limitations and may become inadequate due to changes in conditions or compliance levels over time.
The text provided is indicating that details about legal proceedings can be found in Note 12 of the Condensed Consolidated Financial Statements, which is referenced in the document.
I'm ready for the text parts. Please go ahead and provide the text for me to summarize.
The text provides information on unregistered sales of equity securities and the use of proceeds for a specific period covering July to September 2022. The data includes the total number of shares purchased, average price paid per share, details of shares purchased as part of publicly announced plans or programs, and the maximum number or dollar value of shares that may yet be purchased. The total number of shares purchased during this period was 2,968, with an average price of $143.13 per share. The text further explains that in addition to AbbVie shares repurchased on the open market, these shares also include those purchased for the benefit of participants in the AbbVie Employee Stock Purchase Plan.
I'm ready to receive the text parts for summarization. Please provide them one by one.
I am ready to provide a summary once you provide me with the text to be summarized.
The text provided contains financial information related to AbbVie for the three and nine months ended September 30, 2022. It includes details on interest expense, interest income, and other expenses. Additionally, information on income tax expenses, cash flows, investing and financing activities, dividends, stock repurchase authorization, credit risk, access to capital, credit facility, and credit ratings are outlined. The text also touches on forward-looking statements, market risk, controls and procedures, and legal proceedings. Lastly, it mentions unregistered sales of equity securities and the use of proceeds. The information reflects the company's financial position, liquidity, and critical accounting policies.
The text provides details regarding different exhibits included in a report related to AbbVie Inc., specifically Exhibit Nos. 10.1, 10.2, 31.1, 31.2, 32.1, and 32.2, along with financial statements and notes from the Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 4, 2022. The report also includes the Signature section showing that Scott T. Reents, Senior Vice President and Chief Financial Officer of AbbVie Inc., signed the report on November 4, 2022.
